Category: Research Briefs
Nutrient-Matched Ultraprocessed Meal Triggered a Larger Insulin Response
A randomized crossover study found different short-term insulin, energy-use and brain responses after nutrient-matched ultraprocessed and non-ultraprocessed meals.
Walnuts and visceral fat: what a 12-week randomized trial found
A 12-week randomized trial found faster changes in abdominal-fat measures with a walnut-based lower-carbohydrate diet, but no significant between-group differences at the endpoint.
High-polyphenol olive oil: what the small HEVOOC trial actually shows
A small randomized crossover trial confirms greater phenolic exposure, while metabolic benefits remain exploratory.
Mediterranean diet and the microbiome: a randomized trial found no clear shift
A 24-week randomized trial found no clear group-level microbiome or stool-metabolite change after a Mediterranean-diet intervention.
Sugar, antibiotics, and the microbiome: what a new Nature study found
A new human cohort study, supported by mouse experiments, links sugar-rich eating during antibiotics with deeper gut-microbiome disruption.
Can early type 2 diabetes enter remission? What the RESET trial found
A randomized trial found 54% remission after an intensive supervised diet-and-exercise program, versus 4% with usual care.
NMN raised NAD levels—but did it improve healthy aging?
A 24-week randomized trial found that high-dose NMN raised blood NAD? but did not improve measured physical performance, hearing, glucose, or HbA1c.
Gut microbes and heart failure: new clues, not a probiotic prescription
An observational study links gut microbes with heart-failure severity and improvement, without establishing a probiotic treatment.
Diet, gut microbes, and aging: what a new review can—and cannot—tell us
A new review connects diet and gut microbes with aging-related inflammation, while highlighting the gap between biological mechanisms and proven clinical benefits.
An RNA approach to preserving lean mass during weight loss—in mice
Animal research explores lean-mass preservation during GLP-1 weight loss. Human benefits and safety remain unproven.
Enicepatide trial: promising metabolic results, but heart benefits remain unproven
A sponsor-reported randomized trial found improvements in weight and blood sugar. Full comparisons and long-term cardiovascular outcomes remain uncertain.